还没做过化疗，EGFR是野生型的病友一定要去做ALK的检测

jzjqian 发表于 2012-7-25 15:45

* p2 l' B4 e" c2 n4 B& Z                               
登录/注册后可看大图

请教，像我这样的，手术22个月了，还能去原手术医院拿到病理作EGFR检查么？

可以，但要有针对性，

请问，肺鳞癌，只做过一次化疗，骨髓抑制严重，后吃特罗凯4个月基本无效，可以参加实验组吗？

不可以了,要没做过任何治疗的,包括化疗和靶向药

Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer.  Print this page  


Sub-category:
9 c& [3 [8 o+ X" w+ h3 TMolecular Targets


Category:
. A! `( W" c+ R3 I, x0 bTumor Biology
: f4 Y9 |% j) o: V+ j1 }, r

Meeting:
2011 ASCO Annual Meeting


Session Type and Session Title:
% F( ^/ x7 `- A, u# b+ WPoster Discussion Session, Tumor Biology
2 ~5 y9 Q) j- o. y5 ?2 v% w1 u

/ `* c* @/ {/ D# ^, l. W. Y& l- \Abstract No:
10517
# x3 `# w9 g- k+ S! B

Citation:
J Clin Oncol 29: 2011 (suppl; abstr 10517)
' Q( T" v/ }% W. |% ?  J
0 Y8 R4 F& g: z) e& R+ C; k3 O
Author(s):
J. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China
) M, v7 |7 M8 b. X1 _


Abstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.
, s7 }$ R6 E4 K6 N
Abstract Disclosures
0 b6 L) C, \5 T- J% P
Abstract:
& a5 q" q- C' r4 n

0 g; [* g* C" `- s$ I7 cBackground: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.
0 p$ I  X3 x+ b! T# ]3 K: |

由吴一龙教授牵头的A80810029临床试验上周启动，初诊未治疗的晚期肺腺癌患者检测到ALK阳性，可参加一线crizotinib 对比力比泰+卡铂的临床研究，药物全部免费，即使分配到力比泰组，疾病进展之后可免费获得crizotinib.

没有手术，只化疗过，现吃靶向药，未突变，alk未测，有机会入组吗？

boeun 发表于 2012-11-18 16:37

                               
登录/注册后可看大图

没有手术，只化疗过，现吃靶向药，未突变，alk未测，有机会入组吗？

9 y4 e8 y5 U5 b& B: L化疗过的没机会了

平安！ 发表于 2012-7-20 11:20

                               
登录/注册后可看大图

% [$ r! F- S+ j; |" W易瑞沙、特罗凯有效的病人基本上可以断定ALK（-）。极其罕见EGFR、ALK同时突变的。
ALK一个指标医院要900多 ...

  t) f5 y8 f$ H6 q平安，真的没有希望吗？我弟弟虽然特罗凯有效，但是ＥＧＦＲ是野生型，不是突变啊。有没有必要去检测ＡＬＫ呢？

现在病情进展，快没招儿了。

好像想加入挺困难的

小地方没条件做啊